Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Proximal spinal muscular atrophies are a group of neuromuscular disorders characterized by progressive muscle weakness resulting from the degeneration and loss of the lower motor neurons in the spinal cord and the brain stem nuclei.
Features include very common findings: Skeletal muscle atrophy and Proximal muscle weakness; and common findings: Bulbar palsy, Areflexia, Tongue fasciculations, and Reduced tendon reflexes and others. 50 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 20 | Skeletal muscle atrophy, Proximal muscle weakness, Tongue fasciculations |
A consensus document on the diagnosis of children with spinal muscular atrophy (SMA) was initially developed by and was updated by .
Suggestive Findings
Scenario 1. Abnormal newborn screening (NBS) result
NBS for spinal muscular atrophy (SMA) is primarily based on real-time PCR that detects the common SMN1 deletion and may also detect SMN2 copy number on dried blood spots .
3 FDA-approved treatments are available for proximal spinal muscular atrophy, including NUSINERSEN (SPINRAZA, approved 2016), onasemnogene abeparvovec-xioi (Zolgensma, approved 2019), and RISDIPLAM (EVRYSDI, approved 2020).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
Where available, targeted therapy should be initiated as soon as possible for eligible individuals. A treatment algorithm for the evaluation of presymptomatic infants has been published . Presymptomatic individuals with five copies of SMN2 should be carefully monitored for the development of symptoms to determine appropriate timing to initiate targeted and/or supportive therapies. For those who are receiving a targeted therapy, review of prescribing information and the package insert is suggested, as recommendations for ongoing surveillance are changing rapidly for each targeted therapy. Both potential side effects and new phenotypes associated with targeted treatments continue to emerge. Individuals with SMA are evaluated at least every six months; weaker children are evaluated more frequently. Multidisciplinary surveillance at each visit includes assessments of nutritional state, respiratory function, motor function, and orthopedic status (spine, hips, and joint range of motion) to help determine appropriate interventions.
1 clinical trial registered, 1 recruiting. Interventions under study include biologic therapy. Research is primarily sponsored by academic and government institutions.
178 publications have been identified in PubMed for proximal spinal muscular atrophy. Research spans Review / Meta-Analysis (31%), Epidemiology / Natural History (13%), and Clinical Trial Publication (12%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 55 | 31% |
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 5:33 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Brain and nerves |
6 |
Tongue fasciculations, Difficulty swallowing (dysphagia), Difficulty walking (gait disturbance) |
Lungs and breathing | 6 | Recurrent aspiration pneumonia, Neonatal respiratory distress, Difficulty breathing due to muscle weakness (respiratory insufficiency due to muscle weakness) |
Bones and joints | 4 | Skeletal muscle atrophy, Sideways curvature of the spine (scoliosis), Multiple joint contractures |
Digestive system | 4 | Difficulty swallowing (dysphagia), Constipation, Gastroesophageal reflux |
Pregnancy and birth | 3 | Neonatal respiratory distress, Neonatal hypotonia, Decreased fetal movement |
Head and neck | 2 | Weakness of facial musculature, Facial diplegia |
Heart and blood vessels | 2 | Atrial septal defect, Bradycardia |
Arms and legs | 2 | Distal upper limb muscle weakness, Distal lower limb muscle weakness |
Blood and immune system | 1 | Recurrent infections due to aspiration |
Metabolism | 1 | Metabolic acidosis |
Age of onset: before birth.
Spinal muscular atrophy (SMA) is characterized by muscle weakness and atrophy resulting from progressive degeneration and irreversible loss of the anterior horn cells in the spinal cord (i.e., lower motor neurons) and the brain stem nuclei. The onset of weakness ranges from before birth to adulthood. The weakness is symmetric, proximal greater than distal, and progressive. Before the advent of molecular diagnosis, attempts were made to classify SMA into discrete subtypes; however, it is now apparent that the phenotype of SMA associated with SMN1 pathogenic variants spans a broad continuum without clear delineation of subtypes. Newly approved treatment options are changing the natural history of SMA phenotypes and blurring the boundaries even further . Nonetheless, the existing classification system based on age of onset and maximum function attained with supportive care only is useful for prognosis and management. Table 2. Spinal Muscular Atrophy: Spectrum of Phenotypes at Presentation
Phenotype | Age of Onset | Life Span1 | Motor Milestones1 | Other Findings1 |
|---|---|---|---|---|
SMA 0 | Prenatal | A few weeks, 6 mos | None achieved | Severe neonatal hypotonia; Severe weakness; Areflexia; Respiratory failure at birth; Facial diplegia; fetal movements; Atrial septal defects; Arthrogryposis |
SMA I | 6 mos | Median survival 8-10 mos | Some head control, sit w/support only | Loss of head control; Mild joint contractures; Normal or minimal facial weakness; Variable suck swallow difficulties |
SMA II | 6-18 mos | 70% alive at age 25 yrs | Independent sitting when placed | Developmental delay w/loss of motor skills; or absent deep tendon reflexes; Proximal muscle weakness; Postural tremor of fingers |
SMA III | 18 mos | Normal | Independent ambulation | Proximal muscle weakness (i.e., difficulty w/stairs, running); Loss of motor skills; Fatigue; Postural tremor of fingers; Loss of patellar reflexes |
SMA IV | Adulthood | Normal | Normal | Fatigue; Proximal muscle weakness 1. With supportive care only SMA 0 presents with severe weakness, hypotonia, and respiratory distress at birth. There may be a history of decreased in utero movements, joint contractures, and atrial septal defects. |
Source: GeneReviews — "Spinal Muscular Atrophy"
Source: GeneReviews — "Spinal Muscular Atrophy"
Table 5. Disorders to Consider in the Differential Diagnosis of Spinal Muscular Atrophy
Age of Onset | Disorder | Gene(s) or Region | MOI | Clinical Features of Disorder |
|---|---|---|---|---|
UBA1 | XL | Hypotonia, weakness, areflexia | Multiple congenital contractures, intrauterine fractures SMARD11 (OMIM 604320) | — |
IGHMBP2 | AR | Weakness, respiratory failure, hypo- or areflexia | Distal predominant weakness, diaphragmatic paralysis GARS1-related infantile-onset SMA2 (OMIM 619042) | — |
GARS1 | AD | Hypotonia, weakness, areflexia | Diaphragmatic paralysis, sensory involvement | — |
Prader-Willi syndrome | 15q11.2-q133 | See footnote 3. | Hypotonia, feeding difficulties | Poor respiratory effort is rare. Myotonic dystrophy type 1 |
DMPK | AD | Hypotonia, muscle weakness | Marked facial weakness | — |
Congenital muscular dystrophy | Many genes | ARAD | Hypotonia, muscle weakness | CNS, eye involvement, possible tone |
Zellweger spectrum disorder | PEX family of genes | AR | Hypotonia | Hepatosplenomegaly, CNS |
Congenital myasthenic syndromes | CHATCHRNECOLQDOK7GFPT1RAPSN4 | ARAD | Hypotonia | Ophthalmoplegia, ptosis, episodic respiratory failure Pompe disease |
GAA | AR | Hypotonia | Cardiomegaly | — |
Other: congenital myopathies,5 metabolic/mitochondrial myopathies,6 peripheral neuropathies7 6 mos | Botulism | NA | Proximal muscle weakness, reflexes | Prominent cranial nerve palsies, acute onset |
Later childhood | Guillain-Barr syndrome | NA | Muscle weakness | Subacute onset, sensory involvement Duchenne muscular dystrophy |
DMD | XL | Muscle weakness, motor regression | Serum creatine kinase concentration 10-20x normal Hexosaminidase A deficiency (juvenile, chronic, adult-onset variants) | — |
HEXA | AR | Lower motor neuron disease | Slow progression, progressive dystonia, spinocerebellar degeneration, cognitive/psychiatric involvement Fazio-Londe syndrome (See Riboflavin Transporter Deficiency Neuronopathy.) | SLC52A2 |
SLC52A3 | AR | Progressive bulbar palsy | Limited to lower cranial nerves; progresses to death in 1-5 yrs | — |
Monomelic amyotrophy (Hirayama disease) (OMIM 602440) | Unknown | Muscle weakness | Predominantly cervical; tongue may be affected (rare); other cranial nerves spared | — |
Other: peripheral neuropathies,7 muscular dystrophies8 Adulthood | Spinal bulbar muscular atrophy (Kennedy disease) | — | — | — |
AR | XL | Proximal muscle weakness, muscle atrophy, fasciculations | Gradually progressive; gynecomastia, testicular atrophy, fertility | — |
Amyotrophic lateral sclerosis | Many genes9 | ADARXL | May begin w/pure lower motor neuron signs | Progressive neurodegeneration; involves both upper lower motor neurons AD = autosomal dominant; AR = autosomal recessive; CNS = central nervous system; MOI = mode of inh... |
Source: GeneReviews — "Spinal Muscular Atrophy"
Biomarker and diagnostic research for proximal spinal muscular atrophy has been reported in the published literature.
EVRYSDI |
RISDIPLAM |
— |
2020 |
Available |
Zolgensma | onasemnogene abeparvovec-xioi | — | 2019 | Available |
SPINRAZA | NUSINERSEN | — | 2016 | Available |
Detailed recommendations on management of care in individuals with spinal muscular atrophy (SMA) have been published; see (full text) and (full text). Furthermore, treatment algorithms for infants diagnosed through newborn screen have been published (full text). Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with SMA, the affected individual should be referred to a multidisciplinary clinic. Regardless of SMA subtype, clinical care should be based on an individual's current functional status. Issues to consider are listed in . Table 6. Spinal Muscular Atrophy: Evaluations to Consider Following Initial Diagnosis
System/Concern | Evaluation | Comment |
|---|---|---|
Constitutional | Assessment of growth parameters | Plotted on standard growth chart Gastrointestinal/ |
Feeding | Assessment for feeding dysfunction GERD | Incl evaluation of aspiration risk,1 nutritional status, time required to complete a feed; Consider eval for gastrostomy tube placement in those w/dysphagia /or aspiration risk. Assessment of liver function |
Respiratory | Assessment of pulse oximetry capnography | Consider referral to pulmonologist familiar w/SMA.2 Consider FVC, as appropriate to age. |
Musculoskeletal | Orthopedic/ physical medicine rehab/ PT OT eval | Incl assessment of:; Gross motor fine motor skills; Contractures, hip dislocation, scoliosis; Mobility, ADL, need for adaptive devices3; Need for PT (to improve gross motor skills) /or OT (to improve fine motor skills) |
Hematologic | Assessment for thrombocytopenia coagulation abnormalities | Prior to administration of nusinersen (Spinraza®; antisense oligonucleotide) onasemnogene abeparvovec (Zolgensma®) (See .) Miscellaneous/ |
Other | Consultation w/clinical geneticist /or genetic counselor | Incl genetic counseling Family support resources |
Source: GeneReviews — "Spinal Muscular Atrophy"
Prolonged fasting should be avoided, particularly in the acutely ill infant with SMA .
Source: GeneReviews — "Spinal Muscular Atrophy"
A number of different therapeutic approaches are in development, including further studies on the approved therapeutics discussed above. See the SMA Drug Pipeline maintained by Cure SMA for a list of therapies in preclinical and clinical development phases. SMN2-targeted therapeutic approaches. Therapeutic approaches in this category aim to alter SMN2 splicing to increase the proportion of transcripts containing exon 7 and thus increase full-length survival motor neuron (SMN) protein. Antisense oligonucleotides are single-stranded RNA molecules specifically designed to target complementary sequences in the SMN2 transcript, leading to inclusion of exon 7. Nusinersen and risdiplam work through this mechanism. SMN-independent approaches.
Source: GeneReviews — "Spinal Muscular Atrophy"
1 trial found
Source: GeneReviews — "Spinal Muscular Atrophy"
Phenotype severity distribution: 2 very common features, 21 common features.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
Disease patterns and progression |
24 |
13% |
Clinical study results | 22 | 12% |
New treatment approaches | 21 | 12% |
Testing and diagnosis research | 20 | 11% |
Laboratory research | 19 | 11% |
Patient case studies | 11 | 6% |
Other research | 6 | 3% |
Patel R (2026). [PMID: 41791198](https://pubmed.ncbi.nlm.nih.gov/41791198/). *Pediatric neurology*. [Review / Meta-Analysis]
Okamoto K (2026). [PMID: 42189425](https://pubmed.ncbi.nlm.nih.gov/42189425/). *Adv Ther*. [Review / Meta-Analysis]
Yu Y (2026). [PMID: 41782369](https://pubmed.ncbi.nlm.nih.gov/41782369/). *Mol Ther*. [Gene Therapy / Novel Therapeutics]
Malandrini F (2026). [PMID: 41680498](https://pubmed.ncbi.nlm.nih.gov/41680498/). *Neurol Sci*. [Review / Meta-Analysis]
Alberti C (2026). [PMID: 41817636](https://pubmed.ncbi.nlm.nih.gov/41817636/). *Cell Mol Life Sci*. [Review / Meta-Analysis]
Gnazzo M (2026). [PMID: 41924788](https://pubmed.ncbi.nlm.nih.gov/41924788/). *Sleep Med*. [Review / Meta-Analysis]
Finkel RS (2026). [PMID: 41566720](https://pubmed.ncbi.nlm.nih.gov/41566720/). *Expert Rev Neurother*. [Review / Meta-Analysis]
Jin J (2026). [PMID: 41556253](https://pubmed.ncbi.nlm.nih.gov/41556253/). *Muscle Nerve*. [Diagnostic / Biomarker]
Ottoboni L (2026). [PMID: 41720432](https://pubmed.ncbi.nlm.nih.gov/41720432/). *Neurobiol Dis*. [Review / Meta-Analysis]
Trahan MJ (2026). [PMID: 42203536](https://pubmed.ncbi.nlm.nih.gov/42203536/). *Clin Ther*. [Review / Meta-Analysis]
AI-curated news mentioning proximal spinal muscular atrophy
Updated Sep 7, 2026
A cross-sectional survey investigates the frequency and circumstances of falls in individuals with spinal and bulbar muscular atrophy. This research highlights the need for targeted interventions to reduce fall risks in this patient population.
A recent study highlights the use of muscle MRI as an effective imaging biomarker for assessing muscle damage in patients with spinal and bulbar muscular atrophy. This advancement could enhance monitoring and treatment strategies for affected individuals.
A study published on PubMed evaluates the reliability and construct validity of the Italian version of the AMAT scale in subjects with spinal bulbar muscular atrophy (SBMA). This research contributes to the assessment tools available for this rare disease.